Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -217.00M | -437.00M | -846.00M | -139.00M | 463.00M |
Total Depreciation and Amortization | 269.00M | 259.00M | 259.00M | 272.00M | 266.00M |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 768.00M | 554.00M | 700.00M | 240.00M | 163.00M |
Change in Net Operating Assets | -245.00M | 317.00M | -10.00M | -497.00M | 292.00M |
Cash from Operations | 575.00M | 693.00M | 103.00M | -124.00M | 1.18B |
Capital Expenditure | -129.00M | -148.00M | -97.00M | -124.00M | -119.00M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | 0.00 | -- | -- | -15.00M | -- |
Divestitures | 4.00M | 38.00M | 1.00M | -- | 0.00 |
Other Investing Activities | 327.00M | 378.00M | 274.00M | 283.00M | 420.00M |
Cash from Investing | 202.00M | 268.00M | 178.00M | 144.00M | 301.00M |
Total Debt Issued | -- | -- | -- | -- | 0.00 |
Total Debt Repaid | -685.00M | -- | -956.00M | -- | -500.00M |
Issuance of Common Stock | -- | -- | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 11.00M | -- | -10.00M | -151.00M | -76.00M |
Cash from Financing | -674.00M | -- | -966.00M | -151.00M | -576.00M |
Foreign Exchange rate Adjustments | -121.00M | 100.00M | -49.00M | -104.00M | 68.00M |
Miscellaneous Cash Flow Adjustments | -1.00M | -- | 1.00M | -1.00M | -- |
Net Change in Cash | -19.00M | 1.06B | -733.00M | -236.00M | 977.00M |